ACTU earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -1.28. Updated 2026-07-23.
Actuate Therapeutics (ACTU) Research Hub
Actuate Therapeutics (ACTU) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.07 USD (-15.08%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.28, market cap 0.03B. This hub links to the full technical, earnings and options research available for ACTU.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.07 USD (-15.08%) |
| 52-week range | 0.912 USD – 2.33 USD |
| Trend regime | Range |
| 14-day RSI | 48.9 (Neutral) |
| Trailing P/E | -1.28 |
| Market cap | 0.03B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for ACTU
Covered Call on ACTU: how it works, illustrative setup around the real 1.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ACTU: how it works, illustrative setup around the real 1.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ACTU: how it works, illustrative setup around the real 1.07 USD price, max profit/loss, breakeven and when to use it. Educational.
ACTU technical analysis: range, last 1.07 USD, RSI 48.9, 52w range 0.912 USD–2.33 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ACTU in?
Actuate Therapeutics (ACTU) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ACTU in an uptrend or downtrend?
As of 2026-09-11, ACTU is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ACTU's trailing P/E ratio?
ACTU's trailing P/E is -1.28, with a market cap of 0.03B. See the earnings research page for full valuation detail.
When does ACTU next report earnings?
ACTU is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.21 USD.